Solid tumours

Tumour microenvironment
#Collaboration #Genetics / genomics #Oncology #Solid tumours

AACR data shows promise for patients with solid tumour types

Data from the Friends of Cancer Research’s (Friends’) ctMoniTR Project, recently published in Clinical Cancer Research (CCR), demonstrate a strong association between changes in levels of circulating tumour DNA (ctDNA) and treatment outcomes. This offers the potential for integration of ctDNA analysis in therapeutic development programmes, and clinical cancer… Read More

#Cancer Research #News

#3D modelling #Artificial intelligence (AI) #European Commission #Monoclonal antibodies #Oncology #Solid tumours

This week in drug discovery (7-11 April) 

News round-up for 7-11 April by DDW Senior Digital Content Editor Diana Spencer. As the political news brings more uncertainty for the sector, this week we are focusing on positive developments in the field of oncology, from the possibilities of cancer cures in the rainforest, to a new… Read More

#News

Blushwood tree
#Head and neck cancer #Oncology #Plant-based #QBiotics #Solid tumours #The Institute of Cancer Research

Could a molecule from a rainforest tree treat solid tumour cancers?

Scientists at The Institute of Cancer Research, London, are collaborating with life sciences company QBiotics to understand the molecular and cellular mechanisms of a potential new cancer drug.  The collaborative team will study the effects of tigilanol tiglate – a naturally occurring small molecule derived from the… Read More

#Cancer Research #Editor's Choice #News

Oslo stock exchange
#Cell therapy #Celluna #Natural killer cells #Oncology #Solid tumours

First cell therapy company lists on the Oslo Stock Exchange

Zelluna, a developer of allogeneic ‘off the shelf’ T cell receptor based natural killer (TCR-NK) cells for the treatment of cancer, has announced the successful completion of a Business Combination and Private Placement on the Oslo Stock Exchange.  The share capital increases relating to the issuance of… Read More

#Business & Investment #News

#Breast cancer #Cancer research #Clinical trials #Solid tumours

New DDW Highlights episode: 27 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In the same week that… Read More

#News

#Antibody drug conjugate (ADC) #Bispecific Antibodies #Breast cancer #Oncology #Solid tumours

This week in drug discovery (20-24 January) 

News round-up for 20-24 January by DDW Senior Digital Content Editor Diana Spencer. In the same week that Phesi revealed that breast cancer is the most studied disease for the fourth year in a row, there have been a number of breakthroughs in the treatment of solid tumours,… Read More

#News

Bispecific antibodies
#Bispecific Antibodies #Bispecific therapeutics #Daiichi Sankyo #Oncology #Partnership #Solid tumours

Partners invite proposals for multi-functional biologics research

Daiichi Sankyo and German research institute BioMed X have agreed a new partnership to advance the development of bi- and multi-specific biologics for treating solid tumours.  The new project, entitled ‘New Strategies for Targeting of Solid Tumours with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumours)’, will be… Read More

#Business & Investment #News

#AACR #Cancer research #Clinical trials #Monotherapy #Recursion #Solid tumours

Encouraging response for monotherapy dose-escalation study

Recursion has reported initial monotherapy dose-escalation data from the Phase I/II study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumours. These results were presented after market close at an AACR Special Conference in Cancer Research. “Cell cycle dysregulation and transcriptional ‘addiction’ are both hallmarks of many aggressive… Read More

#Cancer Research #News

Gold compound
#Drug resistance #Oncology #Ovarian cancer #RMIT University #Solid tumours

Gold-based drug slows tumour growth by 82%

Gold-based drugs can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to new research.  The study published in the European Journal of Medicinal Chemistry reveals a new gold-based compound that’s 27 times… Read More

#Cancer Research #Editor's Choice #News

Bispecific antibodies
#Alentis Therapeutics #Antibody drug conjugate (ADC) #Biotechnology #Collaboration #Financing #Novo Holdings #Solid tumours

Successful collaboration to advance ADCs for solid tumours 

Novo Holdings has co-led a $181.4 million Series D financing in Alentis Therapeutics, a clinical-stage biotechnology company, headquartered in Basel, Switzerland, which is developing a pipeline of Claudin-1 (CLDN1) targeted medicines.  This financing will enable Alentis to begin Phase I/II trials for two first-in-class ADCs: ALE.P02, which… Read More

#Business & Investment #News

Cytokines
#Cytokines #Events #Immunotherapy #Oncology #Solid tumours #SOTIO

PD-1-targeting immunocytokine reinvigorates T cells

New data supporting SOT201, a PD-1-targeting immunocytokine, in advanced solid tumours was presented at the 2024 Society for Immunotherapy of Cancer (SITC) Meeting in Houston, TX, US. SOT201 is a PD-1-targeted and cis-acting attenuated IL-15 agonist designed to preferentially activate PD-1+CD8+ T cells, inducing superior anti-tumour… Read More

#Cancer Research #News

Cell therapy
#Cell therapy #Immunotherapy #Oncology #Solid tumours #T cell activation #Turning Science into Business

Are TILs the next big thing in cancer treatment?

DDW’s Megan Thomas speaks with Dr Chantale Bernatchez, Director of Cell Therapy Process Development at CTMC, about tumour infiltrating lymphocyte (TIL) therapy and what’s on the horizon for this new class of cell therapy. TIL therapy is a form of cancer immunotherapy. It’s an autologous cell therapy, meaning cells are… Read More

#Cancer Research #Exclusive Content

Cancer cells
#Aprea Therapeutics #Cancer research #Clinical trials #Solid tumours #Tumour biology

Cancer therapy innovation to overcome traditional limitations 

DDW’s Megan Thomas interviews Dr Oren Gilad, President and CEO of Aprea Therapeutics, about the company’s targeted therapeutics that overcome the traditional issues associated with chemotherapy such as toxicity and tumour resistance.  MT: Can you provide an overview of Aprea Therapeutics’ approach to developing new cancer therapies… Read More

#Cancer Research #Exclusive Content